Current Report Filing (8-k)
September 30 2021 - 05:04PM
Edgar (US Regulatory)
0001510964false00015109642020-08-062020-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 24,
2021
CV SCIENCES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
Delaware |
000-54677 |
80-0944970 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
10070 Barnes Canyon Road
San Diego, California 92121
(Address of principal executive offices)
(866) 290-2157
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant
under any of the following provisions:
☐Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a -12)
☐Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d -2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
|
Title of each class |
Trading Symbol(s) |
Name of exchange on which registered |
N/A |
|
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter). Emerging Growth
Company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers
On September 24, 2021, Dr. Douglas MacKay submitted his resignation
from his position as CV Sciences, Inc.'s Senior Vice President,
Scientific and Regulatory Affairs. Dr. MacKay's last day with CV
Sciences, Inc. is October 8, 2021.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly
authorized.
Date: September 30, 2021
|
|
|
|
|
|
|
CV SCIENCES, INC. |
|
|
|
|
|
|
|
By:
/s/ Joseph Dowling
|
|
Joseph Dowling |
|
Chief Executive Officer |
CV Sciences (QB) (USOTC:CVSI)
Historical Stock Chart
From Apr 2022 to May 2022
CV Sciences (QB) (USOTC:CVSI)
Historical Stock Chart
From May 2021 to May 2022